Lenalidomid Grindeks

Lenalidomide, the active ingredient in Lenalidomid Grindeks, is an immunomodulatory imide drug (IMiD) presented as an oral tablet for oral use. It is used in the treatment of certain blood cancers such as multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomid Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomid Grindeks acts on malignant plasma cells and related pathways in hematologic cancers.

Multiple myeloma: improves progression‑free survival and overall response rates. Myelodysplastic syndromes: reduces transfusion dependence and delays transformation to acute leukemia. Mantle cell lymphoma: contributes to disease control in relapsed or refractory cases.

Lenalidomid Grindeks may cause a range of adverse reactions.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Neutropenia: decreased neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet levels leading to bruising. - Anemia: reduced red blood cell count causing weakness. - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools occasionally observed.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: profound drop in neutrophils requiring medical intervention. - Severe thrombocytopenia: significant platelet loss with bleeding risk. - Secondary primary malignancies: emergence of new cancers. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should assess baseline parameters and monitor patients closely.

Monitor blood counts: perform regular CBC to detect cytopenias. Assess thrombotic risk: evaluate history of clotting disorders before use. Evaluate renal and hepatic function: adjust therapy if organ impairment is present. Avoid in pregnancy: teratogenic potential requires strict contraception. Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lenalidomid Grindeks can interact with several medication classes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase lenalidomide exposure. - Thalidomide or pomalidomide: additive immunomodulatory effects. - Live vaccines: heightened risk of infection. - Anticoagulants (e.g., warfarin): increased bleeding risk. - Anticonvulsants that induce CYP enzymes: may reduce efficacy.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may lower drug levels. - NSAIDs: potential for enhanced gastrointestinal toxicity. - Digoxin: possible altered plasma concentrations. - ACE inhibitors: monitor blood pressure and renal function. - CYP2C19 inhibitors: may modestly affect metabolism.